BPC-157 + TB-500 blend dosing — commonly cited pattern

There is no validated dose for a BPC-157 + TB-500 blend, and there cannot be one yet: no dose-finding study exists for either peptide in humans, and the only controlled study of the pair — a 2026 rat tendon experiment — found the combination no better than either agent alone, which undercuts the premise the product's dosing would be built on (Biçer et al., Jt Dis Relat Surg 2026). What follows describes the patterns that circulate in community logs, and the structural problem fixed-ratio vials create.

When the components are discussed individually in community logs and vendor materials, the frequently repeated ranges are:

• BPC-157: ~250–500 mcg, once or twice daily.
• TB-500: ~2–2.5 mg once or twice weekly as a "loading" phase, then roughly weekly or less.

These figures are anecdotal reference points with no clinical validation. Notably, they do not descend from research: animal studies use weight-based, often intraperitoneal dosing (the Biçer study administered both peptides intraperitoneally) that has no established human conversion, and the human trials that would anchor a real number were never run.

A blend adds a problem single-peptide vials do not have: the ratio. There is no standardized BPC-157:TB-500 ratio — different vendors sell 5 mg/5 mg, 10 mg/10 mg, and other arbitrary splits — and no study has ever compared ratios, because no study of the pair existed at all until 2026. Worse, the two community schedules conflict: the daily-BPC-157 cadence and the weekly-ish TB-500 cadence cannot both be honored by injections drawn from one fixed mixture. Whatever schedule a user picks, one component is being dosed off its own pattern. That is a vendor packaging decision wearing the costume of a protocol.

Blend vials arrive as lyophilized powder for reconstitution with bacteriostatic water before subcutaneous injection.

• Each peptide's mass divided by the diluent volume sets its concentration — the Peptide Calculator maps this out, but with two peptides per vial each draw contains both, in the vial's fixed proportion.
• Dose is read as syringe units of volume, a frequent source of error that a two-peptide solution compounds.
• Peptides are fragile; sterile handling and refrigerated storage after reconstitution matter, and the stability of this particular mixture has never been characterized.

Neither peptide is an approved medicine. BPC-157 sits on the FDA's compounding safety-risk list, where the agency states it lacks sufficient information to know whether the drug would cause harm in humans (FDA), and TB-500 is prohibited in sport at all times under WADA category S2.3. Research-grade purity is not guaranteed, and the interaction, stability, and ratio questions a pre-mixed product raises have never been studied. A qualified clinician can weigh an injury properly — including the evidence-based treatments that exist for most soft-tissue problems. The ranges above describe online consensus, not a recommendation.